Company Filing History:
Years Active: 2014-2016
Title: Klaus Dohler: Pioneering Innovations in Heart Failure Treatment
Introduction
Klaus Dohler, an innovative inventor located in Hannover, Germany, has made significant contributions to the medical field, particularly in the treatment of heart failure. With a total of three patents to his name, his work has been instrumental in developing therapies that improve patient outcomes.
Latest Patents
One of Klaus Dohler's latest patents focuses on the use of natriuretic peptides, specifically urodilatin, for treating patients suffering from heart failure, including acute decompensated heart failure. His research emphasizes the intravenous administration of a composition containing an effective amount of urodilatin, designed to be given continuously over a period of 24 to 120 hours, ideally not less than 48 hours. This innovative approach aims to provide sustained relief and better management of the condition.
Career Highlights
Klaus has worked with prominent companies such as Cardiorentis AG and Cardiopep Pharma GmbH, where he has been involved in groundbreaking projects aimed at enhancing therapeutic options for heart diseases. His expertise and dedication have positioned him as a valuable asset in the field of cardiology.
Collaborations
Throughout his career, Klaus Dohler has collaborated with notable colleagues, including Veselin Mitrovic and Hartmut Luss. These partnerships have fostered an environment of innovation and development, allowing for the cross-pollination of ideas that contribute to advanced medical treatments.
Conclusion
Klaus Dohler stands out as a remarkable inventor whose work in the field of heart failure treatment showcases his commitment to improving patient care through innovative approaches. His patents reflect not only his technical expertise but also a visionary outlook towards future advancements in medicine.